R&D News | pharmaphorum

News

BMS ducks out of $1.56bn TIGIT alliance with Agenus

Bristol-Myers Squibb has handed back rights to a TIGIT drug partnered with Agenus, ending an alliance that could have been worth up to $1.56 billion to the biotech.

News

Bayer's finerenone clears key heart failure trial

At the start of this year, Bayer said there were two important trial readouts for the company to deliver near-term growth this year as it rebuilds its pipeline – and both have now delivered

News

MSD, Daiichi Sankyo lung cancer ADC starts phase 3

One of three antibody-drug conjugates licensed by MSD for $4 billion upfront last year has started phase 3 testing in a form of lung cancer.

News

Anne Wojcicki, CEO and co-founder of 23andMe

23andMe board rebuffs CEO plan to take the firm private

A proposal by 23andMe founder and chief executive Anne Wojcicki to take the genetic testing company private has been rejected by a special committee of the board of directors.

News

uniQure wields axe again as Huntington's therapy progresses

uniQure is shrinking again, saying it will shed two-thirds of its staff by the end of the year – about 300 jobs – as it tries to trim $75 million off its annual cash burn.

News

Lilly gets first heart outcomes readout with tirzepatide

Eli Lilly's dual GLP-1/GIP agonist tirzepatide has been shown to reduce the risk of worsening disease in people with heart failure and obesity in a phase 3 trial, the first to show a benefi

BMS ducks out of $1.56bn TIGIT alliance with Agenus

Bayer's finerenone clears key heart failure trial

MSD, Daiichi Sankyo lung cancer ADC starts phase 3

23andMe board rebuffs CEO plan to take the firm private

uniQure wields axe again as Huntington's therapy progresses

Lilly gets first heart outcomes readout with tirzepatide

UK's Claret Capital raises €575m for European biotechs

Discover a new era of healthcare panel engagement: Grounded ...

News

Editor's Picks